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Three errors have been noted by the author in an article
published in this journal in 2010 [1], all three in paragraphs
three and four under the heading:
“4. Effects of psychotropic drugs on prolactin
secretion”:
1. Reference 19 in the original article [1] (Frazier JA,
et al. Risperidone treatment for juvenile bipolar
disorder: a retrospective chart review. J Am Acad
Child Adolesc Psychiatry. 1999;38:960–5) was quoted
as indicating that one of the 9 of 11 outpatients aged
4–17 years treated with risperidone who developed
hyperprolactinemia had amenorrhea and one had
gynecomastia. In fact, the only hyperprolactinemia
associated complication reported was the one case of
amenorrhea; there were no instances of gynecomastia.
2. Reference 23 in the original article [1] (Bunker MT,
Marken PA, Schneiderhan ME, Ruehter VL.
Attenuation of antipsychotic induced
hyperprolactinemia with clozapine. J Am Acad
Child Adolesc Psychiatry 1997; 7:65–9) was
mistakenly described as reporting a single patient
treated with risperidone who developed
galactorrhea and had resolution of the problem
when switched to clozapine. In fact, the subject had
been treated with thioridazine (haloperidol).
3. The author described reference 24 of the original
article [1] (Findling et al. Prolactin levels during long-
term risperidone treatment in children and adolescents.
J Clin Psychiatry 2003; 64:1362–9), as a retrospective
study of prolactin levels and hyperprolactinemia
attributable side effects from 5 clinical trials involving
592 children and adolescents aged 5–15 years that
yielded a 2.2% frequency of side effects of
gynecomastia, amenorrhea, or galactorrhea, quotingCorrespondence: rosenal@peds.ufl.edu
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reproduction in any medium, provided the orthe published report. However, the frequency noted
in the article was based on Findling et al.
erroneously using the denominator for the entire
5-15-year-old population (n = 592) rather than the
subpopulation that excluded boys over 10 years of
age that they separately analyzed, in order to avoid
confounding by adolescent gynecomastia (n = 360).
It was within this smaller population that the 13
adverse events occurred. The correct frequency for
hyperprolactinemia attributable side effects in these
studies, therefore, should be 3.6% for this
subpopulation and for the entire 5-15-year-old
population in which 30 hyperprolactinemia
attributable side effects occurred, 5%.
The first error, though regrettable, removes a single case
that does not affect the conclusion that, “First-generation
antipsychotics, particularly haloperidol, and the second-
generation antipsychotic drugs, most prominently risperi-
done, appear to be associated with greatest risk for
hyperprolactinemia: some treated individuals develop-
ing hyperprolactinemia will have galactorrhea, amenor-
rhea, or gynecomastia. [1]” The second error, in which
haloperidol rather than risperidone was implicated,
remains consistent with the conclusion. Correction of
the more substantial and significant third error serves
to reinforce this conclusion.
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